There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Steris (STE – Research Report), Pharvaris (PHVS – Research Report) and Dynavax (DVAX – Research Report) with bullish sentiments.
Steris (STE)
JMP Securities analyst David Turkaly reiterated a Buy rating on Steris today and set a price target of $265.00. The company’s shares closed last Wednesday at $210.09.
According to TipRanks.com, Turkaly ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Steris has an analyst consensus of Strong Buy, with a price target consensus of $171.10.
See Insiders’ Hot Stocks on TipRanks >>
Pharvaris (PHVS)
JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Pharvaris today and set a price target of $50.00. The company’s shares closed last Wednesday at $20.85.
According to TipRanks.com, Wolleben is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Pharvaris with a $38.75 average price target.
Dynavax (DVAX)
JMP Securities analyst Roy Buchanan reiterated a Buy rating on Dynavax today and set a price target of $29.00. The company’s shares closed last Wednesday at $11.65.
According to TipRanks.com, Buchanan has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dynavax with a $25.75 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on STE:
- STERIS Announces Financial Results for Fiscal 2024 Fourth Quarter and Full Year
- SPY ETF Update, 5/7/2024
- STE Earnings this Week: How Will it Perform?
- STERIS Announces Dividend of $0.52 per share
- STERIS to Host a Conference Call for Fiscal 2024 Fourth Quarter and Full Year Financial Results on May 9, 2024
